Vaccines remain one of the most effective ways to prevent COVID-19 infections and serious disease. With vaccination rates around the globe still increasing, recent estimates suggest that the majority of adults could be vaccinated against COVID-19 by mid-2022.1 However, current vaccines may not optimally protect against new variants and protection from both natural and vaccine immunity may diminish over time.2
In the rapidly evolving landscape of the pandemic, we have taken a forward-looking approach to our vaccine development. In parallel to our ongoing phase 3 efficacy and safety study for our recombinant vaccine candidate, we have included a study of the vaccine as a potentially broadly protective booster to address evolving public health needs.
Our Adjuvanted Recombinant Protein-based Vaccine Candidate
Our contribution to the global supply
Our Commitment to Fighting COVID-19
Throughout the ongoing pandemic, we have joined forces to fight COVID-19
Frequently Asked Questions (FAQ)
COVID-19 Press Releases
The Impact of COVID-19 on the Prevention and Diagnosis of other Diseases
Vaccines: our best line of defense against infectious diseases like COVID-19
Critical Routine Vaccinations: Getting Back on Track
Preventing the Preventable: Influenza Vaccination in the Time of COVID-19
World Polio Day: Driving Polio Out of Sight, Never Out of Mind
Developing COVID-19 Vaccines: Behind the Scenes
Supporting People with Cancer during COVID-19
COVID-19 Highlights Value of Self-Care as First Line of Defense
References
- GAVI. Covax Global Supply Forecast. Available at: https://www.gavi.org/sites/default/files/covid/covax/COVAX%20Supply%20Forecast.pdf. Last accessed October 2021.
- Nature. COVID vaccines protect against Delta, but their effectiveness wanes. 19 August 2021. Available at: https://www.nature.com/articles/d41586-021-02261-8. Last accessed October 2021